



2021 FCDS DATA ACQUISITION MANUAL OVERVIEW/SUMMARY OF CHANGES

Megsys Herna, BA, CTR
FCDS Virtual Annual conference
August 26, 2021



Florida Cancer Data System



University of Miami Miller
School of Medicine
Fox Building - Room 410
1550 NW 10th Ave
Miami, Florida 33136
or
PO Box 016967 (D4-11)
Miami, Florida 33101

Phone: (305) 243-4600
Fax: (305) 243-4871

**Data
Acquisition
Manual
2021**



Acknowledgements Confidentiality Florida State Law

The Florida Cancer Data System gratefully acknowledges the following sources for their contributions to this manual:

- Centers for Disease Control and Prevention/National Programs of Cancer Registries (CDC/NPCR)
- Florida Department of Health (DOH)
- University of Miami/Sylvester Comprehensive Cancer Center (UM/SCCC)
- North American Association of Central Cancer Registries (NAACCR)
- National Cancer Institute/Surveillance, Epidemiology & End Results Program (NCI/SEER)
- Commission on Cancer/American College of Surgeons (COC/ACoS)

FCDS would like to especially thank all of the dedicated registrars and abstractors who have worked with FCDS over the years for their hard work and countless contributions. Without their input the Florida Cancer Data System would not be positioned at the national forefront in statewide cancer registration.

List of Personnel – Florida Cancer Data System

| | | |
|---|---|--|
| David Lee, PhD | - | Project Director and Principal Investigator |
| Gary M. Levin, BA, CTR | - | Deputy Project Director/Administrative Director |
| Brad Wohler, MS | - | Manager of Statistics |
| Steven Peace, BS, CTR | - | Manager of Quality Control and Education |
| Meggy Hena, BA, CTR | - | Manager of Data Acquisition and Record Consolidation |
| Betty Fernandez, BGS | - | Manager of Administrative Staff |
| Mark Rudolph, MS | - | Manager/Systems Programmer |
| Monique N. Hernandez, PhD | - | Sr. Manager of Data Visualization/Special Projects |
| Anders Alexandersson, MS | - | Senior Research Statistician |
| Melissa Williams | - | Coordinator, Management Systems |
| Edith Alvin | - | Data Acquisition Field Coordinator |
| Anne Auguste, CTR | - | Data Acquisition Field Coordinator |
| Carlos Alvarez, OMD, BHSc, CRC, PA, BBA | - | Data Acquisition Field Coordinator |
| Ofelia Fernandez, CTR | - | Data Acquisition Field Coordinator |
| Betty Malanowski, BS, IMG, CTR | - | Data Acquisition Field Coordinator |
| Brenda Lopez, CTR | - | Data Acquisition Field Coordinator |
| Sasha Raju, MBBS, MPH, CTR | - | Data Acquisition Field Coordinator |
| Saskia Angel, | - | Data Acquisition Field Coordinator |
| Bleu Jeanty Thompson | - | Staff Accountant |
| Danielle Simmons | - | Office Assistant |

List of Personnel – Florida Department of Health, Public Health Research

| | |
|-----------------------------|---|
| Scott A. Rivekes, MD | State Surgeon General and Secretary of Health |
| Shamari Roberson, DrPH, MPH | Deputy Secretary for Health |
| Meredith Hennon, MPH | Registries and Surveillance Manager, Public Health Research |
| Keshia Reid, PhD | Director, Public Health Research |

DAM Section 1

- Guidelines for Cancer Data Reporting
 - Case Eligibility
 - Casefinding
 - Abstracting
 - Data Transmission
 - Psychiatric, Military and Veterans Administration Facilities
 - Ambulatory Surgery Centers
 - Free-Standing Radiation Therapy Centers
 - Private Physician Offices (CAPIS)
 - Clinical Lab Cancer Identification Program (CLIP)
 - FCDS Responsibilities
 - FCDS Management Reports
 - Awards
 - Calendar/Forms/Sample Reports

DAM

Section II

- General Abstracting Instructions
- Cancer Staging Information and Requirements
- Site Specific Data Items
- SEER Summary Stage 2018
- Text Requirements

Appendices A-E

Appendix A: [Florida Healthcare Facilities Currently Reporting to FCDS](#) - UPDATED

Hospitals
Free Standing Surgical Centers
Radiation Therapy Centers
Pathology Labs (e-path) - NEW

Appendix B: [Florida FIPS, USPS State Abbreviations and ISO Country Codes](#)

International Organization for Standardization (ISO) Country Codes
United States Postal Service State Abbreviation Codes
United States Territory Abbreviation Codes
Canadian Province Abbreviation Codes
Federal Information Standards Processing (FIPS) County Codes

Appendix C: [Glossary of Common Terms and Standard Abbreviations](#)

Glossary of Common Terms - UPDATED
NAACCR Recommended Abbreviations List

Appendix D: [Race Coding Instructions and Race and Nationality Descriptions](#)

Race Coding Instructions
Race and Nationality Descriptions from the 2000 Census and
Bureau of Vital Statistics
Other Race Descriptions
Race and Nationality Descriptions Alphabetic Index

Appendix E: [Census List of Spanish Surnames](#)

Spanish Surnames

Appendices F-N

Appendix F: [Site-Specific Surgery Codes](#)

Appendix G: [FCDS 2021 Record Layout \(NAACCR Version 21\)](#)

Appendix H: [2021 FCDS Required Site Data Items \(SSDIs\)](#) - UPDATED

Appendix I: [Free-Standing Radiation Therapy Centers Cancer Case Identification Program](#)

Tab separated file layout for uploads via FCDS IDEA

Data Item Description

Casefinding List – (See Section I or Appendix O for Current Casefinding List)

Appendix J: [Height Conversion Tables - Converting Feet to Inches](#)

Appendix K: [Weight Conversion Tables - Converting Kilograms to Pounds](#)

Appendix L: [FCDS Text Documentation Requirements](#) - UPDATED

Appendix M: [Hematopoietic and Lymphoid Neoplasms](#) - UPDATED

Appendix N: [2021 Grade Coding Instructions and Tables](#) - UPDATED

Appendices O-S

**Appendix O: [2021 FCDS Casefinding Lists for Reportable Tumors](#) – General ICD-10-CM
[ICD-10-CM Casefinding List for Reportable Tumors](#) – Detailed Code List**

Appendix P: [2021 Resources for Registrars](#) – UPDATED

Table of 2021 Resources for Registrars – table of links to required manuals/resources

FCDS Abstracting Basics Course Outline (ABC Course)

Recommended Training Resources for New Registrars

Appendix Q: [Florida DOH Letter Outlining Florida SSN Data Collection Requirement](#)

[FCDS Frequently Asked Questions \(FAQ\)](#)

[Facility Access Administrator \(FAA\) and Responsibilities](#)

[FCDS Profile Modification Form](#)

Appendix R: [ICD-O-3.2 and ICD-O-3 Updates for 2021](#) - NEW

NAACCR Guidelines for Implementation of 2021 ICD-O-3 Updates

2021 ICD-O-3 Update Table 1 – New Behavior Codes (Reportable Neoplasms)

2021 ICD-O-3 Update Table 2 – New Behavior Codes (Non-Reportable Neoplasms)

2021 ICD-O-3 Update Table 3 – Deleted ICD-O Codes in ICD-O-3.2

2021 ICD-O-3 Update Table 4 – Changes in Reportable Terminology

2021 ICD-O-3 Update Table 5 – New Terms and New ICD-O Codes

2021 ICD-O-3 Update Table 6 – Combined 2021 ICD-O-3.2 Update (numerical)

2021 ICD-O-3 Update Table 7 – combined 2021 ICD-O-3.2 Update (alphabetical)

Appendix S: [Summary of 2021 Changes](#) – NEW

FCDS 2021 DAM- Appendix S Summary of Changes

The 2021 FCDS DAM includes clarifications to old instructions, expansion of instructions, new instructions, new data items, new terminology, new reportable cancers, no longer reportable cancers, a new records layout, new requirements for SSDIs, New Codes for existing data items, and many more changes to the 2021 FCDS DAM. We encourage users to review the entire FCDS DAM to ensure they have captured the latest updates and revisions including Appendix P – Resources for Registrars. This is only a Summary of Changes and does not include every single revision in the manual – only major change points. Thank You.

- MOST CHANGES APPEAR IN RED TYPE, BLUE TYPE, OR HIGHLIGHTED SECTIONS – and described here
- Section I has many changes and clarifications – FCDS suggests every registrar read Section I carefully for changes.
- Section I has expanded Section explaining the Requirement for Reporting Non-Analytic Cases and Importance of These Cases
- Section I now has multiple statements describing that FCDS does not at this time allow or receive Update or Modify Records and cannot just update your abstracts when you make a change in your database. FCDS only receives the case from you once.
- Section I has an updated Comparison Table of Reportable Cancers – comparing CoC, SEER, and NPCR/FCDS Requirements.
- Section II has individual data item additions, revisions, updates, new codes, and some updated instructions.
- Section II has expanded the Date of Diagnosis and Definitive Terminology Sections to clarify frequently asked questions about using imaging dates as the Initial Date of DX, Mammography BIRADS and other xyz-RADS Classifications in imaging and how to use, and the need to prioritize Positive Terminology over Ambiguous Terminology on Imaging and how to know the difference.
- Appendix A has been updated to reflect the status of Florida Reporting Facilities in 2021.
- Appendix G has the Complete FCDS 2021 Record Layout including All New Data Items and All Core Data Items
- Appendix H has the Complete FCDS 2021 SSDI Requirements List
- Appendix O has both the abbreviated and the extended versions of the 2021 Casefinding List for Florida
- Appendix P has 2021 Resources for Registrars including all required manuals and references to abstract and code cases.
- Appendix P also has information about the FCDS Abstracting Basics Course Outline and Recommended Training Resources
- Appendix R has all the information about 2021 Updates to ICD-O-3 and How to Use Them

New Reportable Neoplasms

- Early or evolving melanoma, in situ and invasive – now reportable neoplasms
- ALL Gastrointestinal Stromal Tumors (GIST) – now reportable neoplasms
- Most Thymoma Tumors are now reportable neoplasms with Exceptions as Noted –
 - Exceptions include specific thymomas still classified as benign or borderline tumors
 - Exceptions include: microscopic thymoma, thymoma benign, micronodular thymoma with lymphoid stroma and ectopic hamartomatous thymomas.
- LCIS is still reportable to FCDS
- FCDS adopted the full ICD-O-3.2 as of 2018
- Please See Appendix R of the 2021 FCDS DAM for ALL 2021 Updates to ICD-O including Reportability Changes

No Longer Reportable Neoplasms

- Non-invasive follicular thyroid neoplasm with papillary like nuclear features (NIFTP) is a low grade tumor of the thyroid gland and is no longer reportable.
- Dermatofibrosarcoma protuberans has been reclassified as benign/borderline malignancy and is no longer reportable
- Some Immature Teratoma Cases (lung, thymus, thyroid) are no longer classified malignant and are no longer reportable
- Several Cutaneous Lymphoid Diseases have been reclassified as borderline malignancy and are no longer reportable
 - Primary Cutaneous CD4-Positive Small/Medium T-cell Lymphoma
 - Primary Cutaneous CD30_ T Cell Lymphoproliferative Disorder
 - Hydroa Vacciniforme-like lymphoproliferative disorder
 - Langerhans Cell Histiocytosis, NOS
 - Polymorphic Post Transplant Lymphoproliferative Disorder (PTLD)
- Follicular Tumor of Undertain Malignant Potential/Follicular Carcinoma, Encapsulated

New Data Items Required

| Item # | FCDS / NAACCR Item Name |
|--------|---------------------------------|
| 1068 | Grade Post Therapy Clin (yc) |
| 2232 | Name - Birth Surname |
| 2315 | Medicare Beneficiary Identifier |
| 3838 | Gleason Patterns Clinical |
| 3839 | Gleason Patterns Pathological |
| 3840 | Gleason Score Clinical |
| 3841 | Gleason Score Pathological |
| 3842 | Gleason Tertiary Pattern |

New Histological Terms

| ICD-O Code | Term/site |
|------------|--|
| 8273/3 | Pituitary blastoma/ Embryoma |
| 9749/3 | Erdhiem-Chester Disease |
| 9766/3 | Lymphomatoid granulomatosis, grade 3 |
| 9819/3 | B-lymphocytic leukemia/lymphoma, BCR-ABL1-like |
| 9877/3 | Acute myeloid leukemia with mutated NPM1 |
| 9878/3 | Acute myeloid leukemia with biallelic mutations of CEBPA |
| 9879/3 | Acute myeloid leukemia with mutated RUNX1 |
| 9912/3 | Acute myeloid leukemia with BCR-ABL1 |
| 9968/3 | Myeloid/lymphoid neoplasms with PCM1-JAK2 |
| 9993/3 | Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia |
| 9715/3 | Anaplastic large cell lymphoma ALK-negative Breast implant-associated anaplastic large cell lymphoma |

ICD-O-3.2 OBSOLETE CODES

| ICD-O-3.1 Code/behavior | Histological Term(s) |
|----------------------------|--|
| 8471/3 | Papillary mucinous cystadenocarcinoma (C56.9) Papillary pseudomucinous cystadenocarcinoma (C56.9) |
| 9150/3 | Hemangiopericytoma, malignant |
| 9260/3 | Ewing sarcoma |
| 9670/3 | Malignant lymphoma, small B lymphocytic, NOS (<i>see also M-9823/3</i>) Malignant lymphoma, lymphocytic, diffuse, NOS Malignant lymphoma, lymphocytic, NOS Malignant lymphoma, lymphocytic, well differentiated, diffuse Malignant lymphoma, small cell diffuse Malignant lymphoma, small cell, NOS Malignant lymphoma, small lymphocytic, diffuse Malignant lymphoma, small lymphocytic, NOS |
| 9728/3 | Precursor B-cell lymphoblastic lymphoma (<i>see also M-9836/3</i>) |
| 9729/3 | Precursor T-cell lymphoblastic lymphoma (<i>see also M-9837/3</i>) |
| 9826/3 | Burkitt cell leukemia (<i>see also M-9687/3</i>) Acute leukemia, Burkitt type [obs] Acute lymphoblastic leukemia, mature B-cell type B-ALL [obs] FAB L3 [obs] |
| 9836/3 | Precursor B-cell lymphoblastic leukemia (<i>see also M-9728/3</i>) c-ALL Common ALL Common precursor B ALL Pre-B ALL Pre-pre-B ALL Pro-B ALL |
| 9991/3 | Refractory neutropenia |
| 9992/3 | Refractory thrombocytopenia |

FCDS Required SSDI's

| Item # | FCDS/NAACCR Item Name | Start Date |
|--------|---|------------|
| 3800 | Schema ID | 2018 |
| 3816 | Brain Molecular Markers | 2018 |
| 3817 | Breslow Tumor Thickness | 2018 |
| 3827 | Estrogen Receptor Summary | 2018 |
| 3835 | Fibrosis Score | 2018 |
| 3838 | Gleason Patterns Clinical | 2021 |
| 3839 | Gleason Patterns Pathological | 2021 |
| 3840 | Gleason Score Clinical | 2021 |
| 3841 | Gleason Score Pathological | 2021 |
| 3842 | Gleason Tertiary Pattern | 2021 |
| 3843 | Grade Clinical | 2018 |
| 3844 | Grade Pathological | 2018 |
| 1068 | Grade Post Therapy Clin (yc) | 2021 |
| 3845 | Grade Post Therapy Path (yp) | 2018 |
| 3855 | HER2 Overall Summary (breast, esophagus, stomach) | 2018 |
| 3890 | Microsatellite Instability (MSI) | 2018 |
| 3915 | Progesterone Receptor Summary | 2018 |
| 3920 | PSA (Prostatic Specific Antigen) Lab Value | 2018 |
| 3932 | LDH Pretreatment Lab Value | 2018 |

